Fig 1.
Map showing the study sites by treatment regimen.
Fig 2.
Treatment allocation was by block randomization (DA: Diethyl carbamazine plus albendazole and IDA: ivermectin+DA).
Table 1.
Study villages, treatment regimen and demographic features of the study population.
Table 2.
Filarial infection status of the study population prior to treatment.
Table 3.
Age-specific prevalence of CFA and Mf by MDA treatment areas.
Table 4.
Adverse events by age-group, gender and treatment regimen.
Table 5.
Adverse events by microfilaremia (Mf) and treatment regimen.
No AE’s beyond Grade 3 were observed.
Table 6.
Adverse events by circulating filarial antigenemia (CFA) status and treatment regimens.
No AE’s beyond Grade 3 were observed.
Fig 3.
Forest plot showing unadjusted and adjusted odds ratios for factors associated with AE following MDA for filariasis.
Fig 4.
No. of persons with the most commonly observed AE by treatment regimen expressed as percentages of participants who were assessed for AE after treatment.
A participant was counted only once for each AE type (e.g., a subject can only have a single headache). But if a participant experienced different AE types he/she was included in the numerator of each AE type (e.g., if a subject experience a headache and fatigue, then they will be included in the numerator for both of these AE categories). AE, adverse event; DA, double-drug therapy (diethylcarbamazine, albendazole); IDA, triple-drug therapy (ivermectin, diethylcarbamazine, albendazole).
Fig 5.
Information on individuals with filarial infections at baseline and who were retested and retreated 1-year post-treatment.
Table 7.
Reductions in microfilaria (Mf) positivity and geometric mean Mf-count 1-year post-treatment with IDA or DA.
Reduction in Mf-positivity is calculated as % becoming negative for Mf among persons Mf-positive prior to treatment.
Fig 6.
Distribution of subjects who were amicrofilaremic 1 year after treatment by pre-treatment microfilaria count.
Error bars 95% CI based on exact binomial probability distribution.
Fig 7.
Percentage of CFA positives tested positive for Mf prior to and 1-year post treatment with IDA in children, adult and for all ages.
Fig 8.
Percentage of CFA positives tested positive for Mf prior to and 1-year post treatment with DA in children, adult and for all ages.